212 related articles for article (PubMed ID: 32531346)
1. Sicca syndrome following immune checkpoint inhibition.
Mavragani CP; Moutsopoulos HM
Clin Immunol; 2020 Aug; 217():108497. PubMed ID: 32531346
[TBL] [Abstract][Full Text] [Related]
2. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
Warner BM; Baer AN; Lipson EJ; Allen C; Hinrichs C; Rajan A; Pelayo E; Beach M; Gulley JL; Madan RA; Feliciano J; Grisius M; Long L; Powers A; Kleiner DE; Cappelli L; Alevizos I
Oncologist; 2019 Sep; 24(9):1259-1269. PubMed ID: 30996010
[TBL] [Abstract][Full Text] [Related]
3. Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.
Higashi T; Miyamoto H; Yoshida R; Furuta Y; Nagaoka K; Naoe H; Naito H; Nakayama H; Tanaka M
Intern Med; 2020 Oct; 59(20):2499-2504. PubMed ID: 32581160
[TBL] [Abstract][Full Text] [Related]
4. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
5. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer.
Williams KJ; Allen RC
J Neuroophthalmol; 2021 Mar; 41(1):e71-e72. PubMed ID: 32235233
[No Abstract] [Full Text] [Related]
6. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
7. Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma.
Conde-Flores E; Remolina-Bonilla Y; Castro-Alonso F; Martínez-Ibarra N; Hernández-Molina G; Chapa-Ibargüengoitia M; Gamboa-Domínguez A; Bourlon MT
Oncology (Williston Park); 2021 Aug; 35(8):486-490. PubMed ID: 34398593
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
[TBL] [Abstract][Full Text] [Related]
9. Spectrum and impact of checkpoint inhibitor-induced irAEs.
Cappelli LC; Bingham CO
Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330
[No Abstract] [Full Text] [Related]
10. Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up.
Clark HJ; Fong PCC; Ng KPL
Rheumatology (Oxford); 2021 Dec; 61(1):e22-e24. PubMed ID: 34508566
[No Abstract] [Full Text] [Related]
11. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
12. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
Tocut M; Brenner R; Zandman-Goddard G
Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
Cappelli LC; Shah AA; Bingham CO
Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174
[TBL] [Abstract][Full Text] [Related]
15. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
16. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
[TBL] [Abstract][Full Text] [Related]
19. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
20. Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole.
Fink AI; MacKay CJ; Cutler SS
Ophthalmology; 1979 Oct; 86(10):1892-6. PubMed ID: 553260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]